Follow us

Maximilian Kücking advises on complex patent litigation proceedings and technology related issues.

Maximilian Kücking advises clients in the fields of high tech, life sciences and biotechnology on intellectual property issues. He focuses on advising on patent and technology law issues as well as advising and representing clients in patent infringement proceedings.

Maximilian has particular expertise in advising on disputes involving complex technologies such as, i.a., semiconductor technology, telecommunications systems, LEDs, network communications, medical devices, and pharmaceuticals. In addition, he is experienced in handling competition disputes, corporate transactions involving intellectual property and information technologies, and national and international trademark and design enforcement.

Maximilian is a registered representative before the Unified Patent Court (UPC).

Background

Maximilian Kücking graduated from the Humboldt University of Berlin with a focus on Intellectual Property. During his legal clerkship, he worked for another international law firm in the field of patent and utility model infringement proceedings as well as for an international law firm in Tokyo.

Prior to joining Herbert Smith Freehills, Maximilian worked for a leading international law firm. He advises in German and English and has a basic knowledge of Japanese.

Maximilian is listed in "Best Lawyers: Ones to Watch in Germany” for Intellectual Property Law by Best Lawyers/Handelsblatt 2024.

Experience & expertise

Selected matters

  • Millennium Pharmaceuticals, an innovative US-headquartered biopharmaceutical company, and its licensee Johnson & Johnson in the enforcement of patents relating to Velcade®, a first in class drug used to treat multiple myeloma and mantle cell lymphoma in Germany

  • Sanofi in developing litigation strategy for its multiple sclerosis drug, Aubagio, on the basis of data exclusivity rights and intellectual property rights in Germany

  • a multinational technology company in relation to the enforcement of its patent portfolio

  • a U.S. biopharmaceutical company in connection with patents related to medical diagnostics

  • a South Korean technology company in the enforcement of standard essential patents (SEPs) against a global smartphone manufacturer before the Mannheim District Court*

  • a Japanese consumer electronics manufacturer in several German patent infringement cases against leading mobile device and smartphone manufacturers. The disputes included parallel patent infringement proceedings in the U.S. and patent invalidity proceedings in Germany*

  • a leading U.S. pharmaceutical company on infringement of patents for therapeutic antibody drugs*

*Prior to joining Herbert Smith Freehills